These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24190430)

  • 1. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.
    Leung WH; Vong QP; Lin W; Janke L; Chen T; Leung W
    J Exp Med; 2013 Nov; 210(12):2675-92. PubMed ID: 24190430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70.
    Bae JH; Kim JY; Kim MJ; Chang SH; Park YS; Son CH; Park SJ; Chung JS; Lee EY; Kim SH; Kang CD
    J Immunother; 2010 May; 33(4):391-401. PubMed ID: 20386467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.
    Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y
    J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.
    Hu L; Cao D; Li Y; He Y; Guo K
    Cancer Biol Ther; 2012 May; 13(7):516-26. PubMed ID: 22406996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
    Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
    Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
    Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Natural Killer cell expression of ULBP2 is associated with a mature functional phenotype.
    Brennan K; McSharry BP; Keating S; Petrasca A; O'Reilly VP; Keane J; Doherty DG; Gardiner CM
    Hum Immunol; 2016 Oct; 77(10):876-885. PubMed ID: 27349945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
    Front Immunol; 2018; 9():1282. PubMed ID: 29963042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.
    Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M
    J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
    Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
    Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.